Dinámica transcripcional de la Leucemia
Josep Carreras Leukaemia Research Institute
Ctra de Can Ruti, Camí de les Escoles s/n
08916 Badalona, Barcelona
The main interest of our lab is to understand the mechanisms that regulate transcription during normal and malignant haematopoiesis. We employ a combination of genome-wide techniques, genetic engineering tools and advanced microscopy imaging to reveal the genomic regulatory mechanisms that allow blood cells to integrate extracellular signalling information and implement new transcriptional programs. Our ultimate goal is to find molecular vulnerabilities that uncover new therapeutic strategies to treat myeloid malignancies.
Hematopoietic differentiation is a tightly regulated process that ensures a constant flow of blood cell production throughout our lifetime. The transcriptional changes undergone by hematopoietic cells during differentiation are controlled at multiple levels, including transcription factor binding, chromatin modifications and the three-dimensional (3D) genome organization. Accurate integration of all these layers is essential to ensure production of sufficient numbers of blood cells at all stages of differentiation.
Mutations in genes encoding transcriptional regulators and chromatin modifiers are a major driver of acute myeloid leukemia (AML). The defective function of these mutant proteins alters the normal transcriptional dynamics and impairs normal differentiation, giving rise to the outgrowth of malignant clones. To understand how this occurs, we study the mechanisms that regulate transcription during hematopoietic differentiation and investigate the full spectrum of gene deregulation associated to recurrent AML mutations. More specifically, our main goals are:
- To characterize and understand the main transcriptional and epigenetic events in Down syndrome leukemia. Acute megakaryoblastic leukemia is a pediatric leukemia with a strong incidence in children with trisomy 21. The most frequent genomic alterations include mutations in the transcription factor GATA1 and in three-dimensional genome organizer proteins such as cohesin or CTCF. We are investigating the precise role of these proteins in promoting this disease.
- To investigate the three-dimensional genomic landscape regulating Hox gene expression in normal and malignant haematopoiesis. Hox genes encode a large family of homeodomain-containing transcription factors that are essential for normal hematopoietic development. These genes are located in genomic clusters tightly regulated by specific enhancer elements. This accurate control is lost in many cases of AML and is thought to drive malignant clone expansion. We are characterizing the 3D conformation and enhancer landscape of Hox gene clusters in AML.
- To understand the interplay between myeloid-specific mutations and alterations in signalling pathways commonly observed in myeloid malignancies. Inflammatory signals have a strong influence on blood development, and chronic inflammation has been associated to myeloid diseases such as Myelodysplastic Syndromes (MDS). We are investigating the impact of inflammation on the progression of myeloid malignancies and how they are linked to some of the most common epigenetic mutations.
2020 La Caixa Junior Leader
2022 ASH Global Research Award
2022 Ramón y Cajal
Cohesin couples transcriptional bursting probabilities of inducible enhancers and promoters.Nat Commun 27 Jul 2022, 13 (1) 4342. Epub 27 Jul 2022
The Mutational Landscape of Myeloid Leukaemia in Down Syndrome.Cancers (Basel) 18 Ago 2021, 13 (16) . Epub 18 Ago 2021
CTCF is dispensable for immune cell transdifferentiation but facilitates an acute inflammatory response.Nat. Genet. 8 Jun 2020, . Epub 8 Jun 2020
Towards a Better Understanding of Cohesin Mutations in AML.Front Oncol 9 Sep 2019, 9 867.
Control of inducible gene expression links cohesin to hematopoietic progenitor self-renewal and differentiation.Nat Immunol Sep 2018, 19 (9) 932-941. Epub 20 Ago 2018
Descifrando el rol de las mutaciones en el complejo de las cohesinas y la estructura 3D del genoma en leucemia mieloide (MYELO-3D)
|Fecha de inicio:||01/09/2021|
|Fecha de finalización:||31/08/2024|